sorafenib has been researched along with carboxyamido-triazole in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (carboxyamido-triazole) | Trials (carboxyamido-triazole) | Recent Studies (post-2010) (carboxyamido-triazole) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 105 | 15 | 22 |
| Protein | Taxonomy | sorafenib (IC50) | carboxyamido-triazole (IC50) |
|---|---|---|---|
| galanin receptor type 3 | Homo sapiens (human) | 1.8696 | |
| COUP transcription factor 2 isoform a | Homo sapiens (human) | 9.206 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L | 1 |
1 other study(ies) available for sorafenib and carboxyamido-triazole
| Article | Year |
|---|---|
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays | 2017 |